Patents Represented by Attorney Jane M. Love
-
Patent number: 7096073Abstract: A configurable controller, comprising a configurable digital unit having a synchronization control module; a plurality of signal acquisition modules connected with said synchronization control module for receiving reference control data therefrom; and a control logic connected with said plurality of signal acquisition modules; a plurality of identical input cells respectively connected with said plurality of signal acquisition modules, each input cell additionally connected with a respective input pin of said controller; and a synchronizing signal generator connected with said synchronization control module and with said plurality of input cells, for sending synchronization signals to said input cells, wherein each input cell is operable to convert input signal parameters to time-based parameters; and wherein each signal acquisition module is configured to convert said time-based parameters to a required digital form.Type: GrantFiled: September 22, 2003Date of Patent: August 22, 2006Assignee: Creo IL, Ltd.Inventor: Vitaly Burkatovsky
-
Patent number: 6740506Abstract: This invention provides methods of obtaining novel polynucleotides and encoded polypeptides by the use of non-stochastic methods of directed evolution (DirectEvolution™). A particular advantage of end-selection-based methods is the ability to recover full-length polynucleotides from a library of progeny molecules generated by mutagenesis methods. These methods include non-stochastic polynucleotide site-saturation mutagenesis (Gene Site Saturation Mutagenesis™) and non-stochastic polynucleotide reassembly (GeneReassembly™). This invention provides methods of obtaining novel enzymes that have optimized physical &/or biological properties. Through use of the claimed methods, genetic vaccines, enzymes, small molecules, and other desirable molecules can be evolved towards desirable properties. For example, vaccine vectors, can be obtained that exhibit increased efficacy for use as genetic vaccines.Type: GrantFiled: June 19, 2001Date of Patent: May 25, 2004Assignee: Diversa CorporationInventors: Jay M. Short, Gerhard Johann Frey
-
Patent number: 6713279Abstract: This invention provides methods of obtaining novel polynucleotides and encoded polypeptides by use of non-stochastic methods of directed evolution (DirectEvolution™). These methods include non-stochastic polynucleotide site-saturation mutagenesis (Gene Site Saturation Mutagenesis™) and non-stochastic polynucleotide reassembly (GeneReassembly™). Through use of the claimed methods, genetic vaccines, enzymes, and other desirable molecules can be evolved towards desirable properties. For example, vaccine vectors can be obtained that exhibit increased efficacy for use as genetic vaccines. Vectors obtained by using the methods can have, for example, enhanced antigen expression, increased uptake into a cell, increased stability in a cell, ability to tailor an immune response, and the like. This invention provides methods of obtaining novel enzymes that have optimized physical &/or biological properties.Type: GrantFiled: February 4, 2000Date of Patent: March 30, 2004Assignee: Diversa CorporationInventor: Jay M. Short
-
Patent number: 6713282Abstract: This invention provides methods of obtaining novel polynucleotides and encoded polypeptides by the use of non-stochastic methods of directed evolution (DirectEvolution™). A particular advantage of end-selection-based methods is the ability to recover full-length polynucleotides from a library of progeny molecules generated by mutagenesis methods. These methods include non-stochastic polynucleotide site-saturation mutagenesis (Gene Site Saturation Mutagenesis™) and non-stochastic polynucleotide reassembly (GeneReassembly™). This invention provides methods of obtaining novel enzymes that have optimized physical &/or biological properties. Through use of the claimed methods, genetic vaccines, enzymes, small molecules, and other desirable molecules can be evolved towards desirable properties. For example, vaccine vectors can be obtained that exhibit increased efficacy for use as genetic vaccines.Type: GrantFiled: March 14, 2002Date of Patent: March 30, 2004Assignee: Diversa CorporationInventors: Jay M. Short, Gerhard Johann Frey
-
Patent number: 6713281Abstract: Thermostable enzymes are subjected to mutagenesis to produce a thermophilic enzyme which is stable at thermophilic temperature and which has increased activities at least two-fold higher than the activity of the wild-type thermostable enzyme at lower temperatures, which are temperatures of 50° C. or lower.Type: GrantFiled: December 31, 2001Date of Patent: March 30, 2004Assignee: Diversa CorporationInventor: Jay M. Short
-
Patent number: 6709841Abstract: A directed evolution process comprising novel methods for generating improved progeny molecules having desirable properties, including, for example, a method for rapid and facilitated production from a parental polynucleotide template, of a set of mutagenized progeny polynucleotides wherein at least one codon encoding each of the 20 naturally encoded amino acids is represented at each original codon position. This method, termed site-saturation mutagenesis, or simply saturation mutagenesis, is preferably based on the use of the degenerate N,N,G/T sequence. Also, a method of producing from a parental polypeptide template, a set of mutagenized progeny polypeptides wherein each of the 20 naturally encoded amino acids is represented at each original amino acid position.Type: GrantFiled: March 1, 2002Date of Patent: March 23, 2004Assignee: Diversa CorporationInventor: Jay M. Short
-
Patent number: 6696275Abstract: A directed evolution process comprising novel methods for generating improved progeny molecules having desirable properties, including, for example, a method for rapid and facilitated production from a parental polynucleotide template, of a set of mutagenized progeny polynucleotides wherein at least one codon encoding each of the 20 naturally encoded amino acids is represented at each original codon position. This method, termed site-saturation mutagenesis, or simply saturation mutagenesis, is preferably based on the use of the degenerate N,N,G/T sequence. Also, a method of producing from a parental polypeptide template, a set of mutagenized progeny polypeptides wherein each of the 20 naturally encoded amino acids is represented at each original amino acid position.Type: GrantFiled: May 29, 2001Date of Patent: February 24, 2004Assignee: Diversa CorporationInventors: Jay M. Short, Gerhard Johann Frey
-
Patent number: 6665121Abstract: An optical head comprising an array of laser diodes (LDA) where each member of the LDA having a fast axis direction and a slow axis direction of beam divergence, a spatial light modulator (SLM), an imaging lens, and a Micro-Scramblers array (MSA) where each member of the MSA has exit apertures and each member of the MSA is associated with a member of the LDA for scrambling the light only in the direction of the slow axis of the member of the LDA. The optical head can be incorporated into an external-drum electro-optical plotter or a flat bed electro-optical plotter.Type: GrantFiled: November 6, 2001Date of Patent: December 16, 2003Assignee: Creo IL. Ltd.Inventors: Daniel Gelbart, Russell Cork, Nissim Pilossof
-
Patent number: 6635449Abstract: This invention provides methods of obtaining novel polynucleotides and encoded polypeptides by the use of non-stochastic methods of directed evolution (DirectEvolution™). A particular advantage of exonuclease-mediated reassembly methods is the ability to reassemble nucleic acid strands that would otherwise be problematic to chimerize. Exonuclease-mediated reassembly methods can be used in combination with other mutagenesis methods provided herein. These methods include non-stochastic polynucleotide site-saturation mutagenesis (Gene Site Saturation Mutagenesis™) and non-stochastic polynucleotide reassembly (GeneReassembly™). This invention provides methods of obtaining novel enzymes that have optimized physical &/or biological properties. Through use of the claimed methods, genetic vaccines, enzymes, small molecules, and other desirable molecules can be evolved towards desirable properties.Type: GrantFiled: March 26, 2002Date of Patent: October 21, 2003Assignee: Diversa CorporationInventor: Jay M. Short
-
Patent number: 6632600Abstract: Provided is a method of screening gene libraries derived from a mixed population of organisms for a bioactivity or biomolecule of interest. The mixed population of organisms can be a cultured population or an uncultured population from, for example, the environment. Also provided are methods of screening isolates or enriched populations of organisms, which isolates include a population that is spatially, temporally, or hierarchical, for example, of a particular species, genus, family, or class of organisms. Identified clones containing a biomolecule or bioactivity of interest can be further variegated or the DNA contained in the clone can be variegated to create novel biomolecules or bioactivities of interest.Type: GrantFiled: November 15, 2000Date of Patent: October 14, 2003Assignee: Diversa CorporationInventor: Jay M. Short
-
Patent number: 6605449Abstract: Harvesting the full richness of biodiversity is instantly recognized by Diversa Corporation as a powerful means to access both novel molecules having direct commercial utility as well as molecular templates that could be retooled to acquire commercial utility. A directed evolution process for rapid and facilitated production from a progenitor polynucleotide template, of a library of mutagenized progeny polynucleotides wherein each of the 20 naturally encoded amino acids is encoded at each original codon position. This method, termed site-saturation mutagenesis, or simply saturation mutagenesis, is preferably based on the use of the degenerate N,N,G/T sequence. Also, a method of non-stochastically producing a library of chimeric nucleic acid molecules having an overall assembly order that is chosen by design. Accordingly, a set of progenitor templates, such as genes (e.g. a family of esterase genes) or genes pathways (e.g.Type: GrantFiled: June 14, 2000Date of Patent: August 12, 2003Assignee: Diversa CorporationInventor: Jay M. Short
-
Patent number: 6562594Abstract: Disclosed is a rapid and facilitated method of producing from a parentlal template polynucleotide, a set of mutagenized progeny polynculeotides whereby at each original codon position there is produced at least one substitute codon encoding each of the 20 naturally encoded amino acids. Accordingly, there is also provided a method of producing from a parental template polypeptide, a set of mutagenized progeny polypeptides wherein each of the 20 naturally encoded amino acids is represented at each original amino acid position. The method provided is termed site-saturation mutagenesis, or simply saturation mutagenesis, and can be used in combination with other mutagenization processes, such as, for example, a process wherein two or more related polynucleotides are introduced into a suitable host cell such that a hybrid polynucleotide is generated by recombination and reductive reassortment.Type: GrantFiled: January 8, 2001Date of Patent: May 13, 2003Assignee: Diversa CorporationInventor: Jay M. Short
-
Patent number: 6537776Abstract: Harvesting the full richness of biodiversity is instantly recognized by Diversa Corporation as a powerful means to access both novel molecules having direct commercial utility as well as molecular templates that could be retooled to acquire commercial utility. A directed evolution process for rapid and facilitated production from a progenitor polynucleotide template, of a library of mutagenized progeny polynucleotides wherein each of the 20 naturally encoded amino acids is encoded at each original codon position. This method, termed site-saturation mutagenesis, or simply saturation mutagenesis, is preferably based on the use of the degenerate N,N,G/T sequence. Also, a method of non-stochastically producing a library of chimeric nucleic acid molecules having an overall assembly order that is chosen by design. Accordingly, a set of progenitor templates, such as genes (e.g. a family of esterase genes) or genes pathways (e.g.Type: GrantFiled: June 14, 1999Date of Patent: March 25, 2003Assignee: Diversa CorporationInventor: Jay M. Short
-
Patent number: 6506880Abstract: The present invention provides novel synthetic apolipoprotein E (ApoE)-mimicking peptides wherein the receptor binding domain of apolipoprotein E is covalently linked to 18A, the well characterized lipid-associating model class A amphipathic helical peptide. Such peptides enhance low density lipoprotein (LDL) and very low density lipoprotein (VLDL) binding to and degradation b y fibroblast or HepG2 cells. Also provided are possible applications of the synthetic peptides in lowering human plasma LDL/VLDL cholesterol levels, thus inhibiting atherosclerosis.Type: GrantFiled: March 7, 2000Date of Patent: January 14, 2003Assignee: The UAB Research FoundationInventor: Gattadahalli M. Anantharamaiah